
HNGE Stock Forecast & Price Target
HNGE Analyst Ratings
Bulls say
Hinge Health Inc. is experiencing substantial momentum, with expectations of a significant increase in client count in the fourth quarter of 2025, reflecting a strong pipeline for late-stage deals heading into 2026. The company is projecting a robust adjusted operating income margin of approximately 22.4% for the fourth quarter of 2025, which represents a notable improvement of 270 basis points year-over-year. Additionally, Hinge Health delivered an impressive 53.3% revenue growth and expanded its adjusted operating margins by 23 points year-over-year, signaling strong financial health and operational efficiency.
Bears say
Hinge Health Inc. demonstrates a declining adjusted R&D ratio from 23.7% of revenue in 3Q24 to 14.5% in 3Q25, suggesting a potential inability to maintain innovation in a competitive landscape. The bear case scenario anticipates a challenging macroeconomic environment in 2H25, which could lead to slower growth in FY26, compounded by a projected sequential decline in membership for 4Q25. Furthermore, the anticipated mid-teens EBIT margins in 2H25, along with a lower expected EV/revenue multiple due to the firm’s reliance on employee utilization for revenue growth, underscores the financial risks associated with Hinge Health's operational model.
This aggregate rating is based on analysts' research of Hinge Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HNGE Analyst Forecast & Price Prediction
Start investing in HNGE
Order type
Buy in
Order amount
Est. shares
0 shares